Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triplenegative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2017; 18: 1360–72—In the Declaration of interests section of this Article, Jose Baselga’s declarations should read “JB reports non-financial support from Roche/Genentechduring the conduct of the study; personal fees and stock from Aura Biosciences, Northern Biologics (f/k/a Mosaic Biomedicals), Infinity Pharmaceuticals, PMV Pharma, Juno Therapeutics, TANGO (f/k/a Synthetic Lethal), GRAIL, Varian Medical Systems and Seragon; stock from ApoGen Biotechnologies and Foghorn Therapeutics; personal fees and non-financial support from Novartis and Eli Lilly; and non-financial support from Daiichi Sankyo, outside the submitted work.
[Corrections] Correction to Lancet Oncol 2017; 18: 1360–72
Leggi l'articolo originale